The Pointy End of the TGA (PI) Reformatting Transition Period

TGA's new Product Information (PI) Form: If you need support to meet the 31 December 2020 deadline, we’re here to help.

By now, we should all be very familiar with the new Form for providing  TGA Product Information (PI) for Australia Each time you make a change to a PI, be it safety-related or otherwise, you’re required to provide the updated PI to TGA in the new format.

The looming deadline for marketed product PIs to be in the new format is  31 December 2020 . As we are already in mid-March, that’s not very far away. However, more than two thirds of the way through the transition period, a review of a random sample of PIs indicates that approximately  45% of products on the ARTG are still in the old format!

TGA are trying to help Sponsors meet the deadline. To encourage submissions, they have introduced a fee exemption, until the end of the year, for applications where the only change is to reformat the PI and no other editorial changes are made.

What can you do to make the process easier?

  1. Establishing a robust template is extremely important. Although the TGA have provided a bookmarked template, it can be significantly upgraded to include mandatory and standard TGA statements, as well as standardised company preferred text and instructions for the reformatting party.
  2. Documenting PI reformatting decisions and implementing them consistently across the organisation is also key to improving efficiency. Reformatting is not an exact science – variability abounds.

If you need support to meet the 31 December 2020 deadline, we’re here to help.

Our team of regulatory experts and medical writers can efficiently manage your PI reformatting as an outsourced project, relieving the burden on you and your team. Take the stress out of your PI reformatting project today by contacting us.

Contact us today for an initial consultation and learn how we can add value to your business.

More recent articles

  • Regulation of In Vivo CAR‑T Therapies

    Regulation of In Vivo CAR‑T Therapies

    Emerging Regulatory Frameworks for Programmable Immune Engineering Introduction In vivo CAR‑T therapy represents one of the most scientifically disruptive developments in modern biotechnology. Unlike traditional CAR‑T therapies, where T cells are removed from the patient, genetically engineered ex vivo, expanded, and reinfused, in vivo CAR‑T platforms aim to genetically program immune cells directly inside the…

  • From Sequential to Strategic

    From Sequential to Strategic

    How Smart Biotech Companies Are Winning in Accelerated Global Approval Pathways The global biotechnology regulatory environment is no longer just accelerating, it is fragmenting into a set of strategic choices that materially impact time to market, capital efficiency, and valuation. Companies that actively design multi-market regulatory strategies early are gaining measurable advantages. Those that don’t…

  • Orphan and Rare Diseases in 2026

    Orphan and Rare Diseases in 2026

    How Australia Accelerates Global Development A Maturing Global Rare Disease Landscape. In rare diseases, time equals patient impact. Leveraging Australia’s advantages enables faster, smarter global development. What are Orphan and Rare Diseases? Orphan and rare diseases are conditions that affect a small percentage of the population, often defined as impacting fewer than 1 in 2,000…